Innovate Articles
The Patent Term Adjustment Dilemma in an Obviousness-Type Double Patenting Analysis
Babak Akhlaghi
Brief Summary:
This Federal Circuit case delves into the realm of an obviousness-type double patenting (ODP) rejection. An ODP is a US court-created doctrine that restricts applicants from obtaining multiple patents for the same invention. See, In re Lonardo, 119 F.3d 960, 965 (Fed. Cir. 1997). This prevents applicants from extending the period of exclusivity by obtaining a second patent that is obvious over the first, and hence, not patentable over the first patent. To overcome the ODP rejection, a patent applicant can file a terminal disclaimer to disclaim any overlapping terms between the two patents. Interestingly, this case explores whether a Patent Term Adjustment (PTA), which compensates for delays by the USPTO in granting a patent, affects an ODP analysis. The PTA extends the patent's lifespan beyond the standard 20 years from filing. Imagine a scenario where two related patents would have expired simultaneously, but one receives a significant PTA. Can the earlier expiring patent be used to reject the later expiring patent based on double patenting?
The short answer is yes: PTA should indeed be taken into account in the ODP analysis. That is, the determination of ODP is based on patent expiration after the addition of PTA. What makes this case particularly significant is the need to file terminal disclaimers in continuation applications with closely related claims, even in absence of a double patenting rejection. Failure to do so could result in invalidation of these patents based on an ODP rejection if they have a different PTA.
In re Cellect – A Comprehensive Summary:
In In re Cellect, LLC, No. 2022-1293 (Fed. Cir. Aug. 28, 2023), the Federal Circuit held that an obviousness-type double patenting (“ODP”) analysis should be based on the expiration date of a patent with any granted PTA added.
An ODP is a court created doctrine that restricts inventors from obtaining multiple patents for the same invention. See, In re Lonardo, 119 F.3d 960, 965 (Fed. Cir. 1997). This prevents them from extending their exclusivity period by obtaining a second patent that is obvious over their first patent. To overcome the ODP rejection, a patent owner can file a terminal disclaimer to disclaim any overlapping terms between the two patents. Interestingly, this case explores whether a patent term adjustment, which compensates for delays by the USPTO in granting a patent, affects the analysis of ODP. The patent term adjustment extends the patent's lifespan beyond the standard 20 years from filing. Imagine a scenario where two related patents would have expired simultaneously, but one receives a significant patent term adjustment. Can the earlier expiring patent be used to reject the later expiring patent based on double patenting? The answer is yes. Let's dive into the specific details of the case for a clearer understanding.
Cellect owns U.S. Patent Number 6,982,742 (“ ‘742 patent”), U.S. Patent Number 6,424,369 (“ ‘369 patent”), U.S. Patent Number 6,452,626 (“’626 patent”), and U.S. Patent Number 7,002,621 (“ ‘621 patent”), each claiming priority back to an application that issued as U.S. Patent 6,275,255 (“the ’255 patent”). All of the asserted patents are now expired. Each of these patents were granted a Patent Term Adjustment (PTA) due to delays during the prosecution process. Without the PTA, all of these patents would have expired on the same day as the original application. However, due to the PTA, they all expired on different dates.
Cellect sued Samsung for patent infringement of the above patents in the District Court of Colorado. In response, Samsung requested a reexamination of each patent, claiming they were unpatentable based on an ODP rejection. The examiner agreed with Samsung and declared the patents obvious over an earlier expired patent that did not receive a PTA. Cellect appealed to the Board, arguing that the ODP analysis should not take the PTA into account.
Cellect argued that when determining if a patent is unpatentable under ODP, only the expiration dates should be taken into account before any PTA is added to the term. According to Cellect, no ODP should be issued because all the patents in question would have expired on the same date, based on their priority claim to a single application. However, the Board disagreed with this argument, citing that the statutory text of the PTA explicitly states that a PTA cannot extend a term beyond the disclaimed date in any terminal disclaimer. Therefore, the Board concluded that a grant of PTA cannot extend the term of a patent beyond the date stated in a terminal disclaimer. Cellect appealed this decision to the Federal Circuit.
The Federal Circuit agreed with the Board, stating that the ODP analysis must consider patents with PTAs and their extended expiration dates. This ensures that the applicant does not receive an unjust extension of time. The Court also noted that Cellect could have filed a terminal disclaimer to resolve the issue, but it is now too late as all the patents have expired. Therefore, the court concluded that the Board was correct in finding the asserted claims unpatentable under ODP.
A Practice Tip: This is a good reminder for practitioners to review closely related applications in the family and file a terminal disclaimer during their prosecution, even without an ODP. In this case, Cellect missed its opportunity to file a terminal disclaimer during prosecution and it was too late during reexamination as the patents had expired.
Babak Akhlaghi is the Managing Director of NovoTech Patent Firm, a patent law firm specializing in patenting innovations. With extensive experience in preparing and prosecuting patent applications, Babak has had the privilege of representing both multinational corporations and exciting startups. Babak’s outstanding work has been recognized with the prestigious distinction of being a Super Lawyer for five consecutive years since 2019. Babak’s contributions to the field are further highlighted by his co-authorship of the annually updated Patent Applications Handbook, published by West Publications (Clark Boardman Division)